Schizoaffective Disorder, Schizophrenia
Conditions
Brief summary
This is a post-market surveillance, and the treatment to patients will be depended upon the decision based on physician's clinical judgment. The health profiles during the switching period, after 12 weeks short-term use, and after 52 weeks long-term use of aripiprazole will be recorded and evaluated.
Detailed description
Further study details as provided by Taiwan Otsuka Pharmaceutical Co., Ltd.
Interventions
DRUGAripiprazole
Sponsors
Taiwan Otsuka Pharm. Co., Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female patients between the ages of 18 to 65. 2. Having a DSM-IV diagnosis of schizophrenia or schizoaffective disorder. 3. Who are currently taking antipsychotic drugs and clinically intolerable or inadequately controlled that is based upon the clinical judgment of the investigator.
Exclusion criteria
1. Pregnant or breast feeding women or planning a pregnancy. 2. Patient received electroconvulsive therapy within 4 weeks before the Screening Visit. 3. A known allergy reaction to any antipsychotic medication (including but not limited to haloperidol, chlorpromazine, thioridazine, pimozide, risperidone, quetiapine, ziprasidone). 4. Patient has clinically relevant organic, neurological, or cardiovascular diseases. 5. Patient has a history of drug or alcohol abuse within the last 12 weeks. 6. Acute psychosis, acute suicidal ideation, or any acute psychiatric condition that might require emergent intervention. 7. Any clinical condition or significant concurrent disease judged by the investigator to complicate the evaluation of the study treatment. 8. Having participated other investigational drug study and taken the investigation drug within one month prior to study entry. 9. Depot neuroleptics should be discontinued at least 2 months prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in Clinical Global Impression-Severity (CGI-S) scale after 52 weeks treatment. | Throughout the study |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in total score on the Brief Psychiatric Rating Scale (BPRS) at each visit during the treatment period. | Throughout the study. |
| Change from baseline in total score on WHOQOL-BREF questionnaire at each visit during the treatment period. | Throughout the study. |
| Change from baseline in total score on PANSS (optional) questionnaire at each visit during the treatment period. | throughout the study |
| Change from baseline in CGI-S scale at each visit during the first 39 weeks treatment. | Throughout the study |
| Change from Visit 2 on POM questionnaire at each visit during the 12-week switching period. | Throughout the study. |
| CGI-I scores after 12, 26, 39, and 52 weeks of treatment. | Throughout the study. |
| Change from baseline in total score on SFS (optional) questionnaire at 12 and 52 weeks treatment. | Throughout the study. |
Countries
Taiwan
Outcome results
None listed